Date: 2016-03-11
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Genentech, a member of Roche Group (USA - CA - Switzerland)
Product: GDC-0276
Action
mechanism: Nav1.7 inhibitor
Disease: pain
Therapeutic area: CNS diseases - Neurological diseases
Country: UK
Trial
details: This open-label, randomized, 4-way crossover study in healthy participants will determine the relative bioavailability of the tablet formulation relative of GDC-0276 to the capsule formulation and the effect of a high-fat and low-fat meal on the relative bioavailability of the tablet formulation. (NCT02856152)
Latest
news: * On March 11, 2016, a Phase I trial sponsored by Genentech was published on the NIH website ClinicalTrials.gov for GDC-0276.
